Evidence map›Paper›PMID 32358706›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2020

Peripheral neuropathy in Parkinson's disease.

Dion A Paul, Abdul Rehman M Qureshi, Abdul Qayyum Rana

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 51 citations in OpenAlex.

  1. Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Imbalance and gait impairment in Parkinson's disease: discussing postural instability and ataxia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  12. Article
  13. Article
  14. Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Observational
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dion A PaulParkinson's Clinic of Eastern Toronto & Movement Disorders Centre, Toronto, Ontario, M1B 4Z8, Canada. dionpaul@live.ca.
Abdul Rehman M QureshiParkinson's Clinic of Eastern Toronto & Movement Disorders Centre, Toronto, Ontario, M1B 4Z8, Canada.
Abdul Qayyum RanaParkinson's Clinic of Eastern Toronto & Movement Disorders Centre, Toronto, Ontario, M1B 4Z8, Canada.
Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral neuropathy (PN) is a common neurological problem defined as a dysfunction of sensory, motor, and autonomic nerves. The presence of peripheral neuropathy has recently been noticed in Parkinson's disease (PD) This comorbidity is concerning as it increases the burden on patients whose motor functions are previously compromised. A comprehensive computer-based literature review utilizing multiple peer-reviewed databases (e.g., Embase, PsycINFO, CINAHL, etc.) was conducted. There is evidence for the utility of robust diagnostic criteria to distinguish between large fiber neuropathy (LFN) and small fiber neuropathy (SFN). Some studies have established links between prolonged L-DOPA exposure and prevalence with increased levels of homocysteine (HCY) and methylmalonic acid (MMA) as pathological underlying mechanisms. PN in PD patients with relatively truncated exposure to L-DOPA therapy may have underlying mutations in the Parkin and MHTFR gene or separate mitochondrial disorders. Vitamin B12 and cobalamin deficiencies have also been implicated as drivers of PN. Accumulation of phosphorylated α-synuclein is another central feature in PN and deems urgent exploration via large cohort studies. Importantly, these underlying mechanisms have been linked to peripheral denervation. This review delves into the potential treatments for PN targeting B12 deficiencies and the use of COMT inhibitors along with other novel approaches. Avenues of research with powerful randomized controlled and long-term cohort studies exploring genetic mechanisms and novel treatment pathways is urgently required to alleviate the burden of disease exerted by PN on PD.

Indexed as

Parkinson DiseasePeripheral Nervous System DiseasesHumansLevodopaMethylmalonic AcidVitamin B 12LevodopaMethylmalonic AcidVitamin B 12GenesMotor dysfunctionNeurodegenerative disordersParkinson’s diseasePathophysiologyPeripheral neuropathy

Identifiers

PMID32358706
OpenAlexW3023848936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.